Zorecimeran

Zorecimeran is an mRNA vaccine candidate developed by BioNTech and Pfizer for the prevention of COVID-19. It is also known as BNT162b2 or Comirnaty in some regions.

Overview[edit | edit source]

Zorecimeran is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a mutated form of the full-length spike protein of the SARS-CoV-2 virus, which causes COVID-19. The vaccine works by teaching the immune system to recognize and respond to the spike protein, thereby providing immunity against the virus.

Development and Approval[edit | edit source]

The development of Zorecimeran began in early 2020, shortly after the genetic sequence of SARS-CoV-2 was published. The vaccine was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) in December 2020, and full approval was granted in August 2021. It has also been approved for use in many other countries around the world.

Efficacy and Safety[edit | edit source]

Clinical trials have shown that Zorecimeran is highly effective at preventing COVID-19, with an efficacy rate of approximately 95%. The vaccine has been found to be safe, with side effects generally mild and temporary. Common side effects include pain at the injection site, fatigue, headache, muscle pain, chills, joint pain, and fever.

Distribution and Administration[edit | edit source]

Zorecimeran is distributed in multi-dose vials and is administered as a two-dose series, 3 weeks apart. The vaccine must be stored at ultra-cold temperatures, which has posed challenges for distribution in some regions.